Q-omics provides the consensus-scored AMY2B profile across patient tissues and cancer cell-line models. AMY2B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, AMY2B is differentially expressed in 10, with the highest sampling consensus in LUSC. Additionally, AMY2B RNA expression shows 20,396 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight HNSC, LUSC, and LUAD as cancer lineages where AMY2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AMY2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AMY2B survival associations across molecular data types. AMY2B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AMY2B RNA expression–survival associations across cancer types. High AMY2B expression shows unfavorable associations in KIRC, but favorable associations in HNSC, SKCM, ACC, BLCA and STAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for AMY2B RNA expression.
This table summarizes AMY2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in LUSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for AMY2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AMY2B shows lower tumor expression in LUSC, BLCA, UCEC, BRCA and LUAD and higher tumor expression in LIHC. The LUSC box plot shows higher AMY2B RNA expression in normal versus tumor tissue (log2 FC = −0.923, t-test p < 0.001).
This table shows molecular features associated with AMY2B in patient tissues and cancer cell lines. In patient samples, AMY2B shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, AMY2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
